Vivelix Pharmaceuticals, Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vivelix Pharmaceuticals, Ltd.
Approval is unlikely before 2027 but Sweden’s InDex has done the maths and decided that it can launch cobitolimod across the Atlantic on its own with a staff of around 100.
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
- Specialty Pharmaceuticals
- Antisense, Oligonucleotides
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.